Greywolf Therapeutics Advances GRWD0715 Into axSpA Trial
LONDON — September 8, 2026 Greywolf Therapeutics announced that it has dosed the first participants with axial spondyloarthritis (axSpA)...
Genomics
Advertisement
Pillar Biosciences Expands Automated NGS Cancer Workflow
NATICK, MASSACHUSETTS, AND RENO, NEVADA, Aug 27, 2026 Pillar Biosciences, Inc. and Hamilton Company have announced the validation and...
Ernexa Therapeutics Advances ERNA-101 Toward Phase 1 Trial
Cambridge, Massachusetts, August 10, 2026 Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors as...
Genome BC Advances Genomic Health Research in British Columbia
Vancouver, British Columbia, August 11, 2026 Genome BC has announced six research projects supported through its Data Access, Integration...
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Study
PHILADELPHIA, July 31, 2026 Medicus Pharma Ltd. announced that the United Arab Emirates (UAE) Department of Health – Abu...
Advertisements
Haier Biomedical Unveils Digital Blood Management Platform
KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...
Tempus to Acquire Personalis in $1.5B Precision Oncology Deal
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
Novartis to Acquire Myricx Bio for Next-Gen ADC Innovation
BASEL, Switzerland, July 6, 2026 Novartis has announced a landmark agreement to acquire Myricx Bio, a UK-based biotechnology company...
Arima Genomics Partners Active Motif for Hi-C Research
CARLSBAD, California, July 2, 2026 Arima Genomics, Inc., a cancer diagnostics company advancing precision oncology through Hi-C sequencing technology,...
Oxford-Harrington and Oxford Launch £5.25M Pediatric Oncology Program
Oxford, UK and Cleveland, Ohio, US, July 1, 2026 The Oxford-Harrington Rare Disease Centre (OHC) has announced a major...
Advertisement
